Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 and ≤80 years old; 2. Diagnosed with spontaneous subarachnoid hemorrhage through imaging or lumbar puncture; 3. Hunt-Hess score of Ⅲ-Ⅳ; 4. Acute onset, admitted to the hospital within 24 hours of onset Exclusion Criteria: 1. Presence of lung diseases before initiation of study treatment such as chronic obstructive emphysema, bronchiectasis, lung cancer, tuberculosis, or a history of lung surgery; 2. Presence of autoimmune diseases, immune system dysfunction, or blood system dysfunction (absolute lymphocyte count (ALC) less than 0.5×109 cells/L, absolute neutrophil count (ANC) less than 1×109 cells/L, or hemoglobin value less than 8 g/dL) before the onset of the disease; 3. Secondary SAH (such as traumatic SAH), or combined craniocerebral trauma, intraparenchymal hemorrhage, or peripheral organ trauma; 4. Evidence of fever or infection already present at the time of admission; 5. History of previous craniocerebral surgery, previous cerebral hemorrhage, craniocerebral injury, cerebral infarction, intracranial tumor, or presence of neurological dysfunction before the onset of the disease; 6. Presence of contraindications for baricitinib treatment, including severe liver damage, renal dysfunction (creatinine clearance rate \<30ml/min), hypercholesterolemia, or known drug allergies; 7. Taking JAK inhibitors or other immunosuppressive drugs before the onset of the disease; 8. Expected survival time less than 2 weeks; 9. Females who are pregnant or breastfeeding; 10. Currently participating in other interventional clinical studies; 11. Patients who refuse to sign the consent form or refuse to accept follow-up.